This Hated Stock Suddenly Looks Like an Obesity Bargain

Core Insights - Pfizer's recent deal positions the company as a cost-effective entry point into the lucrative weight-loss market [1] Company Summary - The deal is expected to enhance Pfizer's portfolio in the weight-loss sector, which is experiencing significant growth [1] - Pfizer aims to leverage this opportunity to attract a broader customer base seeking affordable weight-loss solutions [1] Industry Summary - The weight-loss industry is witnessing a surge in demand, driven by increasing health awareness and obesity rates [1] - Pfizer's entry into this market could disrupt existing competitors by offering budget-friendly options [1]